WHO ICTRP trial
First line treatment with VeNEtoclaX and ibruTinib induction followed by…
CTIS2022-502808-72-00 · EU Clinical Trials Information System · Not Recruiting
Key facts
| Trial ID | CTIS2022-502808-72-00 |
|---|---|
| Public title | First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in complete remission and/or with detectable bone marrow minimal residual disease (NEXT STEP trial) |
| Scientific title | HOVON 158 CLL: First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in complete remission and/or with detectable bone marrow minimal residual disease (NEXT STEP trial) - HO158 |
| Primary sponsor | Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): Yes Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): No |
| Countries | Netherlands;Denmark |
| Conditions | Chronic Lymphocytic Leukemia;Therapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15];Therapeutic area: Diseases [C] - Neoplasms [C04] |
| Interventions | Product Name: Venclyxto 10 mg film-coated tablets, Product Code:PRD6353818, Pharmaceutical Form: FILM-COATED TABLET, Other descriptive name: , Strength: , Product Name: Gazyvaro 1,000 mg concentrate for solution for infusion., Product… |
| Registration date | Aug 20, 2024 |
| Target size | 85 |
| Secondary IDs | NCT04639362;2019-002528-34 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: